Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis

Crit Care Med. 1997 Dec;25(12):1956-61. doi: 10.1097/00003246-199712000-00009.

Abstract

Objective: To test the hypothesis that adult sheep pretreated with polymyxin-dextran and then made septic by cecal ligation and perforation would have fewer changes in microvascular integrity and cellular architecture in extrapulmonary organs.

Design: Prospective, randomized, double-blind, placebo-controlled animal study.

Setting: An animal research facility in a university-affiliated hospital.

Subjects: Mature, male Suffolk sheep (32 to 67 kg).

Interventions: Animals with chronic indwelling catheters were pretreated with polymyxin B-dextran (6 mg/kg) or placebo (dextran) and an intra-abdominal focus of infection was then produced by cecal ligation and perforation. Treatment (polymyxin B or placebo) was continued every 8 hrs for 48 hrs.

Measurements and main results: Forty-eight hours after randomization, the polymyxin B-dextran group manifested significantly less pyrexia (p = .04), higher mean arterial pressures (p = .02), less variable serum albumin concentrations (p = .05), and a trend toward decreased lactate concentrations (p = .10). Qualitative morphometry and semiquantitative scoring of tissue from gastrocnemius muscle demonstrated that polymyxin B-dextran-treated sheep had significantly increased total capillary (p = .04) and capillary luminal areas (p = .038) and less mitochondrial swelling and damage (p = .03) compared with the placebo sheep.

Conclusions: Pretreatment of sheep in a polymicrobial, peritonitis model of sepsis with polymyxin B-dextran resulted in a significant amelioration of sepsis-induced ultrastructural damage. In placebo-treated control animals, these ultrastructural lesions were associated with a greater severity of sepsis, as measured by the presence of pyrexia, increased lactate concentrations, and less stable blood pressures. These findings justify the investigation of the effects of polymyxin B-dextran in a post onset model of sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Dextrans / administration & dosage
  • Endotoxins / antagonists & inhibitors*
  • Hemodynamics / drug effects
  • Male
  • Muscles / drug effects
  • Muscles / pathology
  • Plasma Substitutes / administration & dosage
  • Polymyxin B / therapeutic use*
  • Premedication
  • Sepsis / prevention & control*
  • Sheep

Substances

  • Anti-Bacterial Agents
  • Dextrans
  • Endotoxins
  • Plasma Substitutes
  • Polymyxin B